Practicality of STAT3 Gene Polymorphisms and Sorafenib Trough Concentration as Biomarkers for Sorafenib-Induced Hand-Foot Skin Reaction in Hepatocellular Carcinoma
Table 5
Logistic regression analysis for HFSR up to day 57.
Total
HFSR onset
HFSR ≥ grade 2
Univariate analysis
Multivariate analysis
Univariate analysis
Multivariate analysis
OR (95% CI)
OR (95% CI)
OR (95% CI)
OR (95% CI)
Age ≥70 years
0.39 (0.10–10.21)
0.18
0.94 (0.28–3.14)
0.92
Female sex
0.99
0.48 (0.07–3.24)
0.46
BW ≥ 61.3 kg
0.20 (0.05–0.88)
0.03
0.09 (0.02–0.37)
<0.01
AFP ≥ 400 ng/mL
0.63 (0.16–2.53)
0.51
0.63 (0.18–2.20)
0.46
Child–Pugh score ≥ 7
4.20 (0.61–28.9)
0.15
3.6 (0.37–35.3)
0.27
Cmedian (μg/mL) ≥ 3.62
14.6 (3.01–71.0)
<0.01
16.6 (3.17–87.3)
<0.01
—
—
—
—
Cmedian (μg/mL) ≥ 6.10
—
—
—
14.3 (3.24–62.5)
<0.01
15.7 (3.27–75.7)
<0.01
rs4796793GC or CC
0.85 (0.13–5.31)
0.86
0.42 (0.05–3.82)
0.51
0.59 (0.10–3.62)
0.57
1.64 (0.18–14.9)
0.66
BW, body weight; AFP, alpha-fetoprotein; Cmedian, sorafenib median concentration.
